media – Page 20 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Shenzhen International Exhibition of Laboratory Medicine and In Vitro Diagnostic Reagents (CEIVD)

Organiser: China Healthcare Industry Association, Chinese Medical Exchange Association Time：December 10 – December 12, 2025 address：No. 1 Zhancheng Road, Fuhai Sub-district, Bao’an District, Shenzhen City, Guangdong Province Exhibition hall：Shenzhen World Exhibition & Convention Center (Bao’an New Venue) Product range: Clinical Laboratory Equipment: Biochemical analyzers, immunoassay analyzers, bacterial analyzers, urine analyzers, microbiological analyzers, electrolyte analyzers, hematology analyzers, hemodialysis machines, microplate readers, chromatographs, PCR instruments, etc. Clinical Laboratory Reagents: In vitro diagnostic reagents, rapid diagnostic reagents, electrolyte reagents, hematology reagents, blood coagulation reagents, blood typing test kits, lipid reagents, biochemical reagents, chemiluminescent reagents, dry chemistry test strips, reagents for chlamydia detection, methamphetamine detection reagents, protein detection reagents, infectious disease detection reagents, tumor marker reagents, human gene detection reagents, immunohistochemistry and human tissue cell reagents, biochips, vitamin assay reagents, cell and tissue chemical staining agents, autoimmune diagnostic reagents, microbiological testing reagents, and other diagnostic reagents. Blood Transfusion-related Products: Blood collection and supply ...
- Source: drugdu
- 131
- July 17, 2025
Danish Study

Early childhood vaccines containing aluminum are not linked to a higher risk for developing autoimmune, allergic, or neurodevelopmental disorders, according to a nationwide study of Danish children. The study, which looked at more than 1.2 million children over 24 years, provides additional evidence supporting the safety of aluminum-adsorbed vaccines, said senior author Anders Peter Hviid, MSc, DMSc, of Statens Serum Institut in Copenhagen. “Our results provide robust evidence to help parents make the right decisions about the health of their children and for clinicians and public health officials to communicate about the excellent safety of the childhood vaccines,” Hviid told Medscape Medical News. “It’s understandable that more and more parents are concerned about vaccine safety, given the mixed messages that they receive currently. We hope that our study can help settle the issue on this particular concern.” Aluminum adjuvants have been used in non-live vaccines to boost immune response for ...
- Source: drugdu
- 110
- July 16, 2025
Household Mold Can Trigger Lung Disease

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Household mold can be a significant trigger for a rare but potentially debilitating lung disease that can cause permanent breathing problems, a new study says. Mold appears to be the primary cause for nearly a quarter (23%) of 231 cases of hypersensitivity pneumonitis (HP) treated at the University of Texas Southwestern Medical Center in Dallas, researchers report in the journal PLOS One. It’s the largest study to date linking home mold exposure to HP, researchers said. HP is an interstitial lung disease, a group of diseases that irritate, inflame or scar lung tissue. “This case series is important because it links home mold exposure with the development of hypersensitivity pneumonitis, which informs our efforts to diagnose and treat interstitial lung diseases,” lead author Dr. Traci Adams, an assistant professor of internal medicine at UT Southwestern, said in a news ...
- Source: drugdu
- 59
- July 16, 2025
U.S. clinical study of ASC47 combined with semaglutide for the treatment of obesity completes dosing of subjects

July 15, Ascletis Pharmaceuticals-B (01672.HK) announced on the Hong Kong Stock Exchange that the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) to evaluate the safety, tolerability and preliminary efficacy of a single subcutaneous injection of ultra-long-acting ASC47 combined with semaglutide in obese subjects without type 2 diabetes on day 29 has recently completed dosing of all 28 subjects. The enrollment of the 28 subjects was completed quickly within two months. “The rapid progress of ASC47 clinical enrollment highlights the industry’s strong interest in weight-loss new therapies and the potential benefits of combination therapy,” said Dr. Jinzi Wu, Founder, Chairman and CEO of Ascletis. “The trial is progressing steadily as planned and is expected to obtain its top-line data in the fourth quarter of 2025.” https://finance.eastmoney.com/a/202507153456982312.html
- Source: drugdu
- 53
- July 16, 2025
Mabwell Biopharma licenses two denosumab injections to Philippine pharmaceutical company UNILAB

On July 14, Mabwell Biopharma announced that the company’s two denosumab injections 9MW0311 (Prolia® biosimilar, domestic trade name: Mylishu®) and 9MW0321 (Xgeva® biosimilar, domestic trade name: Mabwell®) signed a licensing and commercialization agreement with the Philippine pharmaceutical company UNILAB, INC. (hereinafter referred to as “UNILAB”). According to the agreement, UNILAB will be responsible for the registration and sales of the two products in the Philippines, and Mabwell Biopharma will be responsible for the development, production and commercial supply of the products. It is reported that UNILAB is a leading pharmaceutical company in the Philippines, committed to the sales and promotion of high-quality new drugs in the Philippine market. According to IQVIA data, UNILAB ranks first in the pharmaceutical industry of the Association of Southeast Asian Nations with its production, registration and marketing capabilities. In August 2023, Mabwell Biopharma and UNILAB reached a strategic cooperation on adalimumab biosimilars, and the relevant ...
- Source: drugdu
- 68
- July 16, 2025
An IIT study based on an engineered extracellular vesicle mRNA platform to deliver full-length dystrophin for the treatment of Duchenne muscular dystrophy (DMD) has been initiated, opening a new paradigm for gene therapy

Researchers from Shenzhen Bay Laboratory, Shenzhen Academy of Medical Sciences, Peking University Shenzhen Graduate School, and Shanghai Spinoin Biotechnology Co., Ltd. recently collaborated with Shanghai Children’s Medical Center affiliated to Shanghai Jiao Tong University School of Medicine and obtained approval to conduct the world’s first clinical trial using a non-viral vector full-length dystrophin (FL-dystrophin) gene therapy to treat Duchenne muscular dystrophy (DMD) . This is also the first international clinical trial initiated by researchers (IIT) to introduce gene therapy drugs into humans using an extracellular vesicle delivery platform. The project, titled ” A novel mRNA platform based on engineered extracellular vesicles (EVs) to treat Duchenne muscular dystrophy “, aims to deliver FL-dystrophin mRNA through engineered extracellular vesicles, evaluate its safety, tolerability and preliminary efficacy in DMD patients, and provide patients with safer and more efficient gene therapy options. 01 Research background and scientific basis Duchenne muscular dystrophy is a fatal ...
- Source: drugdu
- 74
- July 16, 2025
Sinovent’s new drug application for marketing approval has been accepted, the nemesis of drug-resistant bacteria is here

On July 9, the CDE official website showed that Sinovent’s application for the marketing approval of imipenem-cilastatin sodium fonobactam for injection (hereinafter referred to as imipenem-cilastatin sodium fonobactam for injection) was officially accepted. This world-first new antibacterial drug is intended to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), directly addressing the most difficult problem of drug-resistant bacterial infection in clinical practice. Compared with other new β-lactamase inhibitors (such as avibactam, relebactam, etc.), this product has a wider and stronger inhibitory activity, and can comprehensively and effectively inhibit the common A, C, and D enzyme activities of Gram-negative bacteria. Behind this breakthrough is a key breakthrough in the field of drug-resistant bacteria by a Chinese pharmaceutical company that was established only 8 years ago. In the intensive care unit, hospital-acquired pneumonia and ventilator-associated pneumonia are common life-threatening infections. What is more worrying is that the detection rate of carbapenem-resistant ...
- Source: drugdu
- 69
- July 16, 2025
【EXPERT Q&A】How many types of EU CE certification are there?

Drugdu.com expert’s response: The EU CE certification is primarily classified into three types based on certification modes (COC, AOC, DOC) and multiple types based on product directives, while the certification path also involves different module combinations. Here is a detailed classification and explanation: I. Three Types Based on Certification Modes COC (Certificate of Compliance) Issuing Authority: Third-party organizations (e.g., intermediaries or testing and certification bodies). Content: Typically accompanied by technical documentation (TCF) such as test reports, and enterprises are also required to sign a Declaration of Conformity. Applicable Scenarios: Applicable to a variety of situations, whether for AOC or other products requiring certification under specific modes (e.g., B+D, B+E, H, etc.), a COC certificate may ultimately be obtained. AOC (EC Attestation of Conformity) Issuing Authority: EU Notified Bodies (NB). Content: According to EU regulations, only NB organizations are qualified to issue such certificates. Applicable Scenarios: Typically arises when product certification ...
- Source: drugdu
- 109
- July 16, 2025
Lepu Medical’s Sodium Hyaluronate Solution for Injection is Approved for Registration to Expand Business in the Consumer Healthcare Field

On the evening of July 11, Lepu MedicalDisclosure of a suggestive announcement regarding the registration approval of sodium hyaluronate solution for injection by NMPA. The company learned today that the sodium hyaluronate solution for injection independently developed by its subsidiary Sichuan Xingtai Pule Medical Technology Co., Ltd. has been approved for registration by the National Medical Products Administration (NMPA), with the registration certificate number of National Medical Device Registration No. 20253131324. The product is used in medical institutions for injection into the superficial dermis of the face to temporarily improve dry skin and dull complexion in adults. The announcement pointed out that the sodium hyaluronate solution for injection is a water light injection product. By accurately injecting nutrients into the superficial or middle layers of the dermis, it effectively solves the problem of skin care products being difficult to absorb through the skin. The successful approval of the sodium hyaluronate ...
- Source: drugdu
- 75
- July 15, 2025
Digene Pharmaceuticals’ Suvotinib Tablets are included in the latest version of the NCCN guidelines to create a new paradigm for the internationalization of China’s “original” new drugs

July 12, Digene (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as “Digene Pharmaceutical”) held a press conference in Beijing on the approval of Shuvozal® in the United States. Reporters learned that ZEGFROVY® (generic name: Suvotinib tablets) of Digene Pharmaceuticals has been included in the National Comprehensive Cancer Network (NCCN) non-small cell lung cancer guidelines for the treatment of previously treated epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC). ZEGFROVY® has become the only EGFR exon20ins NSCLC small molecule targeted drug in the world that has been included in the international authoritative lung cancer guidelines. Earlier, Shuwozhe® was approved for marketing by the U.S. Food and Drug Administration (FDA) through priority review on July 3, becoming the world’s first and only EGFRexon20ins NSCLC innovative drug approved in the United States.It is also China’s first independently developed global innovative . Professor Wang Mengzhao of Peking ...
- Source: drugdu
- 75
- July 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.